Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	carboxyl- or carbamoyltransferase activity	CAD OTC	5.61e-05	2	150	2	GO:0016743
GeneOntologyMolecularFunction	high-affinity IgG receptor activity	FCGR1A FCGR1BP	5.61e-05	2	150	2	GO:0019771
GeneOntologyMolecularFunction	leukotriene receptor binding	FCGR1A FCGR1BP	5.61e-05	2	150	2	GO:0031774
Domain	VWF_type-D	ZAN SSPOP SUSD2 MUC5AC	6.23e-06	16	147	4	IPR001846
Domain	VWFD	ZAN SSPOP SUSD2 MUC5AC	6.23e-06	16	147	4	PS51233
Domain	VWD	ZAN SSPOP SUSD2 MUC5AC	6.23e-06	16	147	4	SM00216
Domain	VWD	ZAN SSPOP SUSD2 MUC5AC	6.23e-06	16	147	4	PF00094
Domain	CARBAMOYLTRANSFERASE	CAD OTC	6.15e-05	2	147	2	PS00097
Domain	OTCace	CAD OTC	6.15e-05	2	147	2	PF00185
Domain	OTCace_N	CAD OTC	6.15e-05	2	147	2	PF02729
Domain	Asp_carbamoyltransf_Asp/Orn-bd	CAD OTC	6.15e-05	2	147	2	IPR006131
Domain	Asp/Orn_carbamoyltranf_P-bd	CAD OTC	6.15e-05	2	147	2	IPR006132
Domain	Asp/Orn_carbamoylTrfase	CAD OTC	6.15e-05	2	147	2	IPR006130
Domain	-	CAD OTC	6.15e-05	2	147	2	3.40.50.1370
Domain	C8	ZAN SSPOP MUC5AC	9.98e-05	12	147	3	PF08742
Domain	TIL	ZAN SSPOP MUC5AC	9.98e-05	12	147	3	PF01826
Domain	Lactamase_B	PNKD ETHE1 INTS11	1.29e-04	13	147	3	PF00753
Domain	Unchr_dom_Cys-rich	ZAN SSPOP MUC5AC	1.29e-04	13	147	3	IPR014853
Domain	C8	ZAN SSPOP MUC5AC	1.29e-04	13	147	3	SM00832
Domain	TIL_dom	ZAN SSPOP MUC5AC	1.63e-04	14	147	3	IPR002919
Domain	Lactamase_B	PNKD ETHE1 INTS11	2.03e-04	15	147	3	SM00849
Domain	Aldolase_II	ADD1 ADD2	3.65e-04	4	147	2	SM01007
Domain	Aldolase_II/adducin_N	ADD1 ADD2	3.65e-04	4	147	2	IPR001303
Domain	Aldolase_II	ADD1 ADD2	3.65e-04	4	147	2	PF00596
Domain	-	ADD1 ADD2	3.65e-04	4	147	2	3.40.225.10
Domain	VWC_out	ZAN SSPOP MUC5AC	4.22e-04	19	147	3	SM00215
Domain	-	PNKD ETHE1 INTS11	4.94e-04	20	147	3	3.60.15.10
Domain	Metallo-B-lactamas	PNKD ETHE1 INTS11	4.94e-04	20	147	3	IPR001279
Domain	Cys_knot_C	GPHA2 SSPOP MUC5AC	9.68e-04	25	147	3	IPR006207
Domain	CTCK_2	GPHA2 SSPOP MUC5AC	9.68e-04	25	147	3	PS01225
Domain	-	MROH5 FRYL HSPBP1 MROH6 EFR3B HEATR5B HEATR3	1.91e-03	222	147	7	1.25.10.10
Domain	Peptidase_S8_His-AS	TPP2 PCSK4	2.14e-03	9	147	2	IPR022398
Domain	Peptidase_S8_Ser-AS	TPP2 PCSK4	2.14e-03	9	147	2	IPR023828
Domain	-	CAD GATD1	2.66e-03	10	147	2	3.40.50.880
Domain	Peptidase_S8_subtilisin-rel	TPP2 PCSK4	2.66e-03	10	147	2	IPR015500
Domain	SUBTILASE_ASP	TPP2 PCSK4	2.66e-03	10	147	2	PS00136
Domain	SUBTILASE_HIS	TPP2 PCSK4	2.66e-03	10	147	2	PS00137
Domain	SUBTILASE_SER	TPP2 PCSK4	2.66e-03	10	147	2	PS00138
Domain	VWFC_1	ZAN SSPOP MUC5AC	2.82e-03	36	147	3	PS01208
Domain	-	TPP2 PCSK4	3.23e-03	11	147	2	3.40.50.200
Domain	Peptidase_S8/S53_dom	TPP2 PCSK4	3.23e-03	11	147	2	IPR000209
Domain	Peptidase_S8	TPP2 PCSK4	3.23e-03	11	147	2	PF00082
Domain	VWFC_2	ZAN SSPOP MUC5AC	3.29e-03	38	147	3	PS50184
Domain	VWC	ZAN SSPOP MUC5AC	3.29e-03	38	147	3	SM00214
Domain	Class_I_gatase-like	CAD GATD1	3.86e-03	12	147	2	IPR029062
Domain	VWF_dom	ZAN SSPOP MUC5AC	4.38e-03	42	147	3	IPR001007
Domain	WD40	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	4.47e-03	259	147	7	PF00400
Domain	Dynein_HC_stalk	DNHD1 DNAH3	5.26e-03	14	147	2	IPR024743
Domain	Dynein_heavy_dom-2	DNHD1 DNAH3	5.26e-03	14	147	2	IPR013602
Domain	DHC_N2	DNHD1 DNAH3	5.26e-03	14	147	2	PF08393
Domain	MT	DNHD1 DNAH3	5.26e-03	14	147	2	PF12777
Domain	Ldl_recept_a	TMPRSS9 LDLRAD1 SSPOP	5.32e-03	45	147	3	PF00057
Domain	WD40	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	5.38e-03	268	147	7	SM00320
Domain	ARM-type_fold	MROH5 FRYL HSPBP1 MROH6 EFR3B HEATR5B ARMH3 HEATR3	5.46e-03	339	147	8	IPR016024
Domain	ARM-like	MROH5 FRYL HSPBP1 MROH6 EFR3B HEATR5B HEATR3	5.59e-03	270	147	7	IPR011989
Domain	-	TMPRSS9 LDLRAD1 SSPOP	5.66e-03	46	147	3	4.10.400.10
Domain	WD40_repeat	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	5.82e-03	272	147	7	IPR001680
Domain	DHC_fam	DNHD1 DNAH3	6.04e-03	15	147	2	IPR026983
Domain	Dynein_heavy	DNHD1 DNAH3	6.04e-03	15	147	2	PF03028
Domain	Dynein_heavy_dom	DNHD1 DNAH3	6.04e-03	15	147	2	IPR004273
Domain	LDLRA_1	TMPRSS9 LDLRAD1 SSPOP	6.38e-03	48	147	3	PS01209
Domain	WD_REPEATS_1	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	6.53e-03	278	147	7	PS00678
Domain	WD_REPEATS_2	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	6.66e-03	279	147	7	PS50082
Domain	WD_REPEATS_REGION	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	6.66e-03	279	147	7	PS50294
Domain	TPR-contain_dom	IFIT1 CRNKL1 TMTC4 TANC1 CDC27	6.71e-03	150	147	5	IPR013026
Domain	LDrepeatLR_classA_rpt	TMPRSS9 LDLRAD1 SSPOP	6.75e-03	49	147	3	IPR002172
Domain	LDLa	TMPRSS9 LDLRAD1 SSPOP	6.75e-03	49	147	3	SM00192
Domain	LDLRA_2	TMPRSS9 LDLRAD1 SSPOP	6.75e-03	49	147	3	PS50068
Domain	Ank_2	ANKRD55 ANKRD46 ANKRD44 TNKS TANC1 ANKRD33B	7.16e-03	215	147	6	PF12796
Pubmed	A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction.	FCGR1A FCGR1BP C5AR1	1.65e-06	6	153	3	10623857
Pubmed	MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice.	FCGR1A FCGR1BP C5AR1	1.65e-06	6	153	3	22025304
Pubmed	Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation.	FCGR1A FCGR1BP C5AR1	2.88e-06	7	153	3	15728518
Pubmed	Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.	FCGR1A FCGR1BP C5AR1	4.60e-06	8	153	3	16453025
Pubmed	C5a initiates the inflammatory cascade in immune complex peritonitis.	FCGR1A FCGR1BP C5AR1	4.60e-06	8	153	3	15322209
Pubmed	Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a.	FCGR1A FCGR1BP C5AR1	1.34e-05	11	153	3	19795417
Pubmed	Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcγRI Reduce Immune Complex Binding and Downstream Effector Functions.	FCGR1A FCGR1BP	1.92e-05	2	153	2	28814603
Pubmed	ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.	ZDHHC11B ZDHHC11	1.92e-05	2	153	2	28331227
Pubmed	Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan.	FCGR1A FCGR1BP	1.92e-05	2	153	2	37733444
Pubmed	Modulating IgG effector function by Fc glycan engineering.	FCGR1A FCGR1BP	1.92e-05	2	153	2	28289219
Pubmed	Amelioration of Lupus Serum-Induced Skin Inflammation in CD64-Deficient Mice.	FCGR1A FCGR1BP	1.92e-05	2	153	2	35273604
Pubmed	Association between hypertension and variation in the alpha- and beta-adducin genes in a white population.	ADD1 ADD2	1.92e-05	2	153	2	12427140
Pubmed	IgG3-mediated enhancement of the antibody response is normal in Fc gammaRI-deficient mice.	FCGR1A FCGR1BP	1.92e-05	2	153	2	16305642
Pubmed	Congenic mapping of the insulin-dependent diabetes (Idd) gene, Idd10, localizes two genes mediating the Idd10 effect and eliminates the candidate Fcgr1.	FCGR1A FCGR1BP	1.92e-05	2	153	2	9257847
Pubmed	Fcγ receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1.	FCGR1A FCGR1BP	1.92e-05	2	153	2	21124939
Pubmed	Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.	FCGR1A FCGR1BP	1.92e-05	2	153	2	24430180
Pubmed	Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.	PHLPP1 PHLPP2	1.92e-05	2	153	2	24892992
Pubmed	[Expression of G-CSF and GM-CSF receptors on CD34 positive cells in aplastic anemia and myelodysplastic syndrome patients and its significance].	CSF2RA CSF3R	1.92e-05	2	153	2	19099633
Pubmed	Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity.	FCGR1A FCGR1BP	1.92e-05	2	153	2	38885133
Pubmed	Primary structure and domain organization of human alpha and beta adducin.	ADD1 ADD2	1.92e-05	2	153	2	1840603
Pubmed	Mild spherocytic hereditary elliptocytosis and altered levels of alpha- and gamma-adducins in beta-adducin-deficient mice.	ADD1 ADD2	1.92e-05	2	153	2	10845937
Pubmed	Novel Fc gamma receptor I family gene products in human mononuclear cells.	FCGR1A FCGR1BP	1.92e-05	2	153	2	1430234
Pubmed	The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE.	FCGR1A FCGR1BP	1.92e-05	2	153	2	15835266
Pubmed	Extracellular mutations of non-obese diabetic mouse FcgammaRI modify surface expression and ligand binding.	FCGR1A FCGR1BP	1.92e-05	2	153	2	8663283
Pubmed	The interaction of N-glycans in Fcγ receptor I α-chain with Escherichia coli K1 outer membrane protein A for entry into macrophages: experimental and computational analysis.	FCGR1A FCGR1BP	1.92e-05	2	153	2	25231998
Pubmed	Lentivirus-mediated knockdown of FcγRI (CD64) attenuated lupus nephritis via inhibition of NF-κB regulating NLRP3 inflammasome activation in MRL/lpr mice.	FCGR1A FCGR1BP	1.92e-05	2	153	2	30190171
Pubmed	PHLPP isoforms differentially regulate Akt isoforms and AS160 affecting neuronal insulin signaling and insulin resistance via Scribble.	PHLPP1 PHLPP2	1.92e-05	2	153	2	36376971
Pubmed	Molecular cloning and expression of the mouse high affinity Fc receptor for IgG.	FCGR1A FCGR1BP	1.92e-05	2	153	2	2136886
Pubmed	Gene organization of the human high affinity receptor for IgG, Fc gamma RI (CD64). Characterization and evidence for a second gene.	FCGR1A FCGR1BP	1.92e-05	2	153	2	1830050
Pubmed	FcRγ deficiency improves survival in experimental sepsis by down-regulating TLR4 signaling pathway.	FCGR1A FCGR1BP	1.92e-05	2	153	2	30552619
Pubmed	Sensory Neuron Expressed FcγRI Mediates Postinflammatory Arthritis Pain in Female Mice.	FCGR1A FCGR1BP	1.92e-05	2	153	2	35833115
Pubmed	Differential gene expression modulated by the cytoplasmic domain of Fc gamma RIa (CD64) alpha-chain.	FCGR1A FCGR1BP	1.92e-05	2	153	2	15528358
Pubmed	Functional characteristics of the high affinity IgG receptor, FcγRI.	FCGR1A FCGR1BP	1.92e-05	2	153	2	21325219
Pubmed	Fc receptors and the common gamma-chain in experimental autoimmune encephalomyelitis.	FCGR1A FCGR1BP	1.92e-05	2	153	2	14991835
Pubmed	Definition of interferon gamma-response elements in a novel human Fc gamma receptor gene (Fc gamma RIb) and characterization of the gene structure.	FCGR1A FCGR1BP	1.92e-05	2	153	2	1402657
Pubmed	PHLPPing through history: a decade in the life of PHLPP phosphatases.	PHLPP1 PHLPP2	1.92e-05	2	153	2	27913677
Pubmed	FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo.	FCGR1A FCGR1BP	1.92e-05	2	153	2	8611682
Pubmed	Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma.	PHLPP1 PHLPP2	1.92e-05	2	153	2	25793736
Pubmed	Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.	FCGR1A FCGR1BP	1.92e-05	2	153	2	16409296
Pubmed	Mouse FcgammaRI: identification and functional characterization of five new alleles.	FCGR1A FCGR1BP	1.92e-05	2	153	2	10752630
Pubmed	Fcγ Receptor Type I (CD64)-Mediated Impairment of the Capacity of Dendritic Cells to Activate Specific CD8 T Cells by IgG-opsonized Friend Virus.	FCGR1A FCGR1BP	1.92e-05	2	153	2	30744065
Pubmed	Serum anti-Fcgamma receptor autoantibodies in patients with alopecia areata.	FCGR1A FCGR1BP	1.92e-05	2	153	2	17124586
Pubmed	Neuronal FcγRI mediates acute and chronic joint pain.	FCGR1A FCGR1BP	1.92e-05	2	153	2	31211699
Pubmed	Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice.	FCGR1A FCGR1BP	1.92e-05	2	153	2	8480181
Pubmed	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.	FCGR1A FCGR1BP	1.92e-05	2	153	2	29576375
Pubmed	Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase Acts as a Tumor Suppressor in Oral Squamous Cell Carcinoma.	PHLPP1 PHLPP2	1.92e-05	2	153	2	38602289
Pubmed	Amelioration of crescentic glomerulonephritis by RhoA kinase inhibitor, Fasudil, through podocyte protection and prevention of leukocyte migration.	FCGR1A FCGR1BP	1.92e-05	2	153	2	18245810
Pubmed	Reconstitution of allogeneic hemopoietic stem cells: the essential role of FcR gamma and the TCR beta-chain-FCp33 complex.	FCGR1A FCGR1BP	1.92e-05	2	153	2	16849450
Pubmed	Ras-associating domain proteins: a new class of cyclic nucleotide-gated channel modulators.	PHLPP1 PHLPP2	1.92e-05	2	153	2	22183406
Pubmed	Biochemical characterization of murine Fc gamma RI.	FCGR1A FCGR1BP	1.92e-05	2	153	2	8478020
Pubmed	FcγR-binding affinity of monoclonal murine IgG1s carrying different N-linked Fc oligosaccharides.	FCGR1A FCGR1BP	1.92e-05	2	153	2	31554601
Pubmed	CD64 plays a key role in diabetic wound healing.	FCGR1A FCGR1BP	1.92e-05	2	153	2	38524127
Pubmed	Intra-erythrocyte cation concentrations in relation to the C1797T beta-adducin polymorphism in a general population.	ADD1 ADD2	1.92e-05	2	153	2	17301826
Pubmed	alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.	ADD1 ADD2	1.92e-05	2	153	2	19838659
Pubmed	Developmentally ordered appearance of a functional Fc gamma receptor on TCR V gamma 3 thymocytes. Evidence for stimulation-induced expression.	FCGR1A FCGR1BP	1.92e-05	2	153	2	8077658
Pubmed	Testis-specific hnRNP is expressed in colorectal cancer cells and accelerates cell growth mediating ZDHHC11 mRNA stabilization.	ZDHHC11B ZDHHC11	1.92e-05	2	153	2	35384384
Pubmed	Sexually dimorphic expression of the X-linked gene Eif2s3x mRNA but not protein in mouse brain.	EIF2S3B EIF2S3	1.92e-05	2	153	2	16325480
Pubmed	Loss of PHLPP protects against colitis by inhibiting intestinal epithelial cell apoptosis.	PHLPP1 PHLPP2	1.92e-05	2	153	2	26187040
Pubmed	The involvement of FcR mechanisms in antibody-mediated rejection.	FCGR1A FCGR1BP	1.92e-05	2	153	2	18049118
Pubmed	Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.	FCGR1A FCGR1BP	5.75e-05	3	153	2	16841095
Pubmed	Nephrotoxic nephritis is mediated by Fcgamma receptors on circulating leukocytes and not intrinsic renal cells.	FCGR1A FCGR1BP	5.75e-05	3	153	2	12427132
Pubmed	Epistatic interaction between alpha- and gamma-adducin influences peripheral and central pulse pressures in white Europeans.	ADD1 ADD2	5.75e-05	3	153	2	15834281
Pubmed	The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression.	HBP1 CREBBP	5.75e-05	3	153	2	21967847
Pubmed	Downregulation of PHLPP induced by endoplasmic reticulum stress promotes eIF2α phosphorylation and chemoresistance in colon cancer.	PHLPP1 PHLPP2	5.75e-05	3	153	2	34663797
Pubmed	MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I.	FCGR1A FCGR1BP	5.75e-05	3	153	2	22287715
Pubmed	Tpl2 kinase regulates FcγR signaling and immune thrombocytopenia in mice.	FCGR1A FCGR1BP	5.75e-05	3	153	2	23898046
Pubmed	Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis.	PHLPP1 PHLPP2	5.75e-05	3	153	2	20513427
Pubmed	Pleckstrin Homology (PH) Domain Leucine-rich Repeat Protein Phosphatase Controls Cell Polarity by Negatively Regulating the Activity of Atypical Protein Kinase C.	PHLPP1 PHLPP2	5.75e-05	3	153	2	27760826
Pubmed	PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells.	PHLPP1 PHLPP2	5.75e-05	3	153	2	32294598
Pubmed	Targeted disruption of the beta adducin gene (Add2) causes red blood cell spherocytosis in mice.	ADD1 ADD2	5.75e-05	3	153	2	10485892
Pubmed	Assignment of the human beta-adducin gene (ADD2) to 2p13-p14 by in situ hybridization.	ADD1 ADD2	5.75e-05	3	153	2	7490111
Pubmed	Serine phosphorylation of FcγRI cytoplasmic domain directs lipid raft localization and interaction with protein 4.1G.	FCGR1A FCGR1BP	5.75e-05	3	153	2	22003208
Pubmed	Expression and role of oncogenic miRNA-224 in esophageal squamous cell carcinoma.	PHLPP1 PHLPP2	5.75e-05	3	153	2	26245343
Pubmed	microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2.	PHLPP1 PHLPP2	5.75e-05	3	153	2	23846336
Pubmed	The phosphatase PHLPP controls the cellular levels of protein kinase C.	PHLPP1 PHLPP2	5.75e-05	3	153	2	18162466
Pubmed	Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.	FCGR1A FCGR1BP	5.75e-05	3	153	2	12594281
Pubmed	Role of the adducin family genes in human essential hypertension.	ADD1 ADD2	5.75e-05	3	153	2	15716695
Pubmed	Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression.	FCGR1A FCGR1BP	5.75e-05	3	153	2	15880819
Pubmed	PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.	PHLPP1 PHLPP2	5.75e-05	3	153	2	17386267
Pubmed	ZDHHC19 localizes to the cell membrane of spermatids and is involved in spermatogenesis†.	ZDHHC11B ZDHHC11	5.75e-05	3	153	2	34897408
Pubmed	A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.	FCGR1A FCGR1BP	5.75e-05	3	153	2	28924242
Pubmed	Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.	FCGR1A FCGR1BP	5.75e-05	3	153	2	9892619
Pubmed	Residual LCMV antigen in transiently CD4+ T cell-depleted mice induces high levels of virus-specific antibodies but only limited B-cell memory.	FCGR1A FCGR1BP	5.75e-05	3	153	2	30636035
Pubmed	Cutting Edge: Drebrin-Regulated Actin Dynamics Regulate IgE-Dependent Mast Cell Activation and Allergic Responses.	FCGR1A FCGR1BP	5.75e-05	3	153	2	26056254
Pubmed	The essential role of complement in antibody-mediated resistance to Salmonella.	FCGR1A FCGR1BP	5.75e-05	3	153	2	30179254
Pubmed	The three genes of the human FCGR1 gene family encoding Fc gamma RI flank the centromere of chromosome 1 at 1p12 and 1q21.	FCGR1A FCGR1BP	5.75e-05	3	153	2	8697799
Pubmed	Transcriptional and post-transcriptional regulation of IκB-ζ upon engagement of the BCR, TLRs and FcγR.	FCGR1A FCGR1BP	5.75e-05	3	153	2	23728777
Pubmed	FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation.	FCGR1A FCGR1BP	5.75e-05	3	153	2	22493081
Pubmed	FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways.	FCGR1A FCGR1BP	5.75e-05	3	153	2	16543474
Pubmed	Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII.	AQP2 F8	5.75e-05	3	153	2	18515885
Pubmed	Escherichia coli K1 induces pterin production for enhanced expression of Fcγ receptor I to invade RAW 264.7 macrophages.	FCGR1A FCGR1BP	5.75e-05	3	153	2	24161960
Pubmed	Gly460Trp alpha-adducin mutation as a possible mechanism leading to endolymphatic hydrops in Ménière's syndrome.	ADD1 ADD2	5.75e-05	3	153	2	18667944
Pubmed	A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population.	CNTN4 KIAA0825	5.75e-05	3	153	2	22318345
Pubmed	Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis.	FCGR1A FCGR1BP	5.75e-05	3	153	2	12707052
Pubmed	Immunofluorescence localization of an adducin-like protein in the chromosomes of mouse oocytes.	ADD1 ADD2	5.75e-05	3	153	2	1864459
Pubmed	FcgammaRI ligation leads to a complex with BLT1 in lipid rafts that enhances rat lung macrophage antimicrobial functions.	FCGR1A FCGR1BP	5.75e-05	3	153	2	19657115
Pubmed	Arterial properties in relation to genetic variations in the adducin subunits in a white population.	ADD1 ADD2	5.75e-05	3	153	2	18787518
Pubmed	Erythrocyte adducin: a calmodulin-regulated actin-bundling protein that stimulates spectrin-actin binding.	ADD1 ADD2	5.75e-05	3	153	2	3693401
Pubmed	Sez6l2 regulates phosphorylation of ADD and neuritogenesis.	ADD1 ADD2	5.75e-05	3	153	2	29032200
Pubmed	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection.	FCGR1A FCGR1BP	5.75e-05	3	153	2	33032297
GeneFamily	WD repeat domain containing	PPP2R2D WDR7 GNB1L SEC31B WDR87 WDR90 WDR24	3.10e-04	262	89	7	362
GeneFamily	Ankyrin repeat domain containing	ANKRD55 ANKRD46 ANKRD44 TNKS TANC1 ANKRD33B	1.24e-03	242	89	6	403
GeneFamily	Maestro heat like repeat containing	MROH5 MROH6	1.28e-03	11	89	2	636
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	IFIT1 TMTC4 TANC1 CDC27	2.50e-03	115	89	4	769
GeneFamily	Protein phosphatases, Mg2+/Mn2+ dependent	PHLPP1 PHLPP2	3.11e-03	17	89	2	701
ToppCell	NS-moderate-d_07-13-Epithelial-FOXN4+\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DNAH3 FOXN4 KIAA0825 CC2D2A CEP295 WDR90 PCSK4 HYDIN	7.04e-08	157	152	8	410c9d74a2085179cfb39853cb6d330fa98c9c1b
ToppCell	metastatic_Lymph_Node-Myeloid_cells-Microglia/Mac\|Myeloid_cells / Location, Cell class and cell subclass	DNHD1 PITRM1 FAM200A ANKRD44 FCSK BBS12 MUC5AC	1.91e-06	169	152	7	dba8f5599aa21feef5b7fdfed2e3ab54748d80f7
ToppCell	3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.0.4.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IFIT1 FCSK CRNKL1 KIAA0825 ANGPT4 ZNF426 WDR24	1.98e-06	170	152	7	79420950d5e4b5da9f52d2a8a8ce096ae44a5edf
ToppCell	Control-Epithelial_alveolar-AT_1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 GSAP MAL2 SUSD2 MYRF	2.69e-06	178	152	7	aa7d43c655df493f1330a5001efaa484e4a19f69
ToppCell	Control-Epithelial_alveolar-AT_1-AT1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PRSS35 ROR1 CLIC3 GSAP MAL2 SUSD2 MYRF	2.69e-06	178	152	7	1817bc520f3d23da8c0fa09bba50ae703a820cb1
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1-AT1_L.0.5.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CNTN4 RCHY1 ROR1 CLIC3 SCUBE1 SUSD2 MYRF	2.79e-06	179	152	7	d5e3e7f1cd8f683f39a7416f12af7e766dcbead8
ToppCell	COPD-Epithelial-ATI\|World / Disease state, Lineage and Cell class	GPR39 ROR1 CLIC3 MAL2 SCUBE1 SUSD2 MYRF	3.12e-06	182	152	7	e95d946a43b1579af199900bb0e3eacbb9d65300
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 GSAP MAL2 SUSD2 MYRF	3.60e-06	186	152	7	3aebe163799109ffc67e4e10ee47c2dd0886a92c
ToppCell	AT1-AT2_cells-Donor_01\|World / lung cells shred on cell class, cell subclass, sample id	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF ANKRD33B	3.86e-06	188	152	7	be710bc957118cf426dd71c2d57e6f1b41c9a467
ToppCell	(7)_Epithelial-I_(AT1)\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	ROR1 CLIC3 MAL2 SCUBE1 SUSD2 EFR3B MYRF	5.07e-06	196	152	7	150554fa06868d29b0608189862eef6505ba757f
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	VWA3A DNAH3 ADGB KIAA0825 WDR90 ZDHHC11 HYDIN	5.25e-06	197	152	7	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	Control_saline-Hematopoietic_Erythro-Megakary-Erythro-Mega\|Control_saline / Treatment groups by lineage, cell group, cell type	TMPRSS9 HMBS FAXDC2 PNKD IFIT1 CYP4F22 PHLPP2	5.42e-06	198	152	7	1a39a98beef68e1e6d3adc25270a3336fcc5baf4
ToppCell	Control_saline-Hematopoietic_Erythro-Megakary-Erythro-Mega-Erythroid\|Control_saline / Treatment groups by lineage, cell group, cell type	TMPRSS9 HMBS FAXDC2 PNKD IFIT1 CYP4F22 PHLPP2	5.42e-06	198	152	7	dd80fd9671ee863aebcf4c1023d3e004cc2ee709
ToppCell	Control_saline-Hematopoietic_Erythro-Megakary\|Control_saline / Treatment groups by lineage, cell group, cell type	TMPRSS9 HMBS FAXDC2 PNKD IFIT1 CYP4F22 PHLPP2	5.42e-06	198	152	7	cfc2a860bae883299987d3e374d0476ca20e1bdd
ToppCell	LPS_anti-TNF-Hematopoietic_Erythro-Megakary-Erythro-Mega-Erythroid\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	TMPRSS9 HMBS FAXDC2 PNKD IFIT1 CYP4F22 PHLPP2	5.61e-06	199	152	7	565404c155dfac57c020a8f2d09cbf756da20ffd
ToppCell	Lung_Parenchyma-Control-Epithelial-Epithelial-AT1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ROR1 CLIC3 MAL2 SCUBE1 SUSD2 EFR3B MYRF	5.79e-06	200	152	7	c6f211bbadd0c9be776c58807249e06764df47dc
ToppCell	Lung_Parenchyma-Control-Epithelial-Epithelial-AT1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	ROR1 CLIC3 MAL2 SCUBE1 SUSD2 EFR3B MYRF	5.79e-06	200	152	7	5f7e8d8b05c90a10313775f9f126eb4ab0fe4f67
ToppCell	Parenchyma_Control_(B.)-Epithelial-TX-AT1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	ROR1 CLIC3 MAL2 SCUBE1 SUSD2 EFR3B MYRF	5.79e-06	200	152	7	e3a80626941363bfc9d97ef906d38c97080aecb1
ToppCell	(05)_Ciliated-(1)_24hpi\|(05)_Ciliated / shred by cell type and Timepoint	PRSS35 PITRM1 GPR39 ETHE1 SMIM33	1.29e-05	88	152	5	76959e7e3f6fae07c9881a29c28ba847be406694
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c5-GSTP1(high)OASL(low)\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	SAMD9 RCBTB2 IFIT1 FCGR1A FCGR1BP ZDHHC11	2.07e-05	163	152	6	d005115aa1e1458b51de7eb719794617a4168608
ToppCell	PCW_07-8.5-Epithelial-Epithelial_ciliated-epi_ciliated_(14)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	VWA3A KCNH8 LDLRAD1 GPR39 MAL2 HYDIN	2.21e-05	165	152	6	0c714e852f912b5749de4cb0895406673979b2e6
ToppCell	PCW_07-8.5-Epithelial-Epithelial_ciliated\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	VWA3A KCNH8 LDLRAD1 GPR39 MAL2 HYDIN	2.21e-05	165	152	6	82530f96aaefe28a13bad0474bbad043f127a86c
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated-Ciliated_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	VWA3A DNAH3 LDLRAD1 ZP3 ADGB HYDIN	2.45e-05	168	152	6	fa7c0303918cea04e3f4c4f3cb079be19004d214
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	VWA3A DNAH3 LDLRAD1 ZP3 ADGB HYDIN	2.45e-05	168	152	6	7edcab103c69e928d5c19a0d218ffb3ae32f9e70
ToppCell	367C-Epithelial_cells-Epithelial-I_(AT1)-\|367C / Donor, Lineage, Cell class and subclass (all cells)	GPR39 CLIC3 MAL2 SUSD2 ZDHHC11 MYRF	2.98e-05	174	152	6	edf839d79ac58921f4e788f3b2cb2ae0d6af4b9e
ToppCell	367C-Epithelial_cells-Epithelial-I_(AT1)\|367C / Donor, Lineage, Cell class and subclass (all cells)	GPR39 CLIC3 MAL2 SUSD2 ZDHHC11 MYRF	2.98e-05	174	152	6	65539f69100db0b7d90b1b39ee15ab8281f86461
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c4-RSAD2\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	SAMD9 SIGLEC14 C1orf74 IFIT1 FCGR1BP MACROH2A2	3.08e-05	175	152	6	97616bb5c127284aa9e67bc336dfcf29e137164b
ToppCell	AT1_cells-Donor_04\|World / lung cells shred on cell class, cell subclass, sample id	ZDHHC11B ROR1 CLIC3 SUSD2 EFR3B MYRF	3.28e-05	177	152	6	3128b8d04687acee1ac4190b2569d6328b98eaf3
ToppCell	Control-Epithelial_alveolar-AT_1-Differentiating_AT1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 GSAP SUSD2 MYRF	3.28e-05	177	152	6	9af14a056eb6d88c6f11b09f6d4c0d3448d647d5
ToppCell	droplet-Spleen-SPLEEN-1m-Lymphocytic-plasma_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PINLYP RCBTB2 SSPOP ANKRD55 OOSP1 LTBP3	3.39e-05	178	152	6	b902059c3f861108fc64cbdc05e6f44378f5be2c
ToppCell	droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Mesenchymal-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GPR39 C1orf74 AQP2 UTP25 YDJC SOAT2	3.50e-05	179	152	6	e880c507f11ce75d104593a4ca29f0295f8125e8
ToppCell	5'-Adult-Appendix-Hematopoietic-Myeloid-LYVE1+_Macrophage\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ZMYND15 SSPOP CSF2RA CSF3R GATD1 C5AR1	3.61e-05	180	152	6	66c7b02d85e32ba3e7530d0c4aff17e7525ccdd8
ToppCell	Ciliated_cells-A-Donor_07\|World / lung cells shred on cell class, cell subclass, sample id	VWA3A LDLRAD1 ADGB WDR90 MUC5AC HYDIN	3.61e-05	180	152	6	d9be152773fe9f2160edad9246fa03c03afeafd6
ToppCell	Control-Epithelial_alveolar-AT_1-AT1-AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 CLIC3 GSAP MAL2 MYRF ANKRD33B	3.84e-05	182	152	6	a95956ce4adccb34cc0c47ebfa1878ce4617904e
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 MAL2 SUSD2 MYRF	3.95e-05	183	152	6	274483009b309289e4cb84beedf6806430db6ff6
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CAD XDH SLC22A8 MACROH2A2 TANC1 ERMARD	4.08e-05	184	152	6	a6dee97ee4ef9d89e11d17339e0dadaea1210ce5
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 GSAP MAL2 MYRF	4.08e-05	184	152	6	42ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell	E18.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	VWA3A DNAH3 LDLRAD1 ZP3 ADGB HYDIN	4.08e-05	184	152	6	797b6a6d6f6aafae98f75ca8bffe8263f8d3ff9b
ToppCell	E18.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated-Ciliated_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	VWA3A DNAH3 LDLRAD1 ZP3 ADGB HYDIN	4.08e-05	184	152	6	77d5b60a20b277f589b18f7a131142a7ef2dac17
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1-D175\|Adult / Lineage, Cell type, age group and donor	CNTN4 GPR39 ROR1 EFR3B TANC1 MYRF	4.20e-05	185	152	6	32b4e68e551d435a732f253f6ad83408c759a642
ToppCell	NS-moderate-d_16-33-Epithelial-Ciliated\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	4.20e-05	185	152	6	5e689c2fb36ce3ac2adc8d15f67107f21cf68868
ToppCell	Control-Epithelial_alveolar\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 GSAP MAL2 MYRF	4.20e-05	185	152	6	3937e026add96a396122139daf8011cfbc60e75c
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	GPR39 ROR1 CLIC3 GSAP MAL2 MYRF	4.20e-05	185	152	6	c82eab551f65ecebe6db908eda9f9eb3414693c7
ToppCell	NS-moderate-d_07-13-Epithelial-Ciliated\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	4.33e-05	186	152	6	85787ff207f109ec7e3c0f729ba9bda739c2fdc9
ToppCell	COPD-Epithelial-ATI\|COPD / Disease state, Lineage and Cell class	GPR39 ROR1 CLIC3 MAL2 SUSD2 MYRF	4.33e-05	186	152	6	df0977f6f48a2d4e11b59971f098b01204242f0f
ToppCell	Control-Epithelial-ATI\|Control / Disease state, Lineage and Cell class	ROR1 CLIC3 MAL2 SCUBE1 SUSD2 MYRF	4.46e-05	187	152	6	fdd1c57b61ca9392ac27661a82729f37593df63c
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c5-CD16\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	BCKDK HMBS PNKD CYFIP1 CSF2RA C5AR1	4.46e-05	187	152	6	5917bdfe84cf5941e21b415aebbab3090cc5d576
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1\|Adult / Lineage, Cell type, age group and donor	CNTN4 GPR39 ROR1 EFR3B TANC1 MYRF	4.46e-05	187	152	6	77f78aec946bc6bd85c29aee9ca978ce49f853a3
ToppCell	COPD-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	VWA3A DNAH3 LDLRAD1 ADGB KIAA0825 HYDIN	4.73e-05	189	152	6	3e77883db34722b9ce0a03ea74caefc92dc7feff
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	IFIT1 CYFIP1 CSF2RA FCGR1A CSF3R C5AR1	4.87e-05	190	152	6	4498705c5c1c7ba88a26fd2f412cf1aadd0f572a
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1-AT1_L.0.5.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.02e-05	191	152	6	a15e34ad7dbf3f2f13d5e23ce3ffb6d08fd1f9f0
ToppCell	LAM-Epithelial-AT1\|LAM / Condition, Lineage and Cell class	ROR1 CLIC3 MAL2 SCUBE1 SUSD2 MYRF	5.02e-05	191	152	6	66875b2ec2c510489407f3e433a90cdf74a15094
ToppCell	LA-03._Atrial_Cardiomyocyte\|LA / Chamber and Cluster_Paper	FBXO40 ACO2 ROR1 TRIM55 TANC1 MYO18B	5.02e-05	191	152	6	5d1b674eb7703830b7ce8bbeac3363cabd0e6ae9
ToppCell	(12)_SLC16A7+\|World / shred by cell type by condition	VWA3A DNAH3 LDLRAD1 ADGB C5AR1 HEATR3	5.02e-05	191	152	6	e427eeddd2e87c14376a37db0b43f120c90436bc
ToppCell	COPD-Epithelial\|COPD / Disease state, Lineage and Cell class	VWA3A GPR39 MAL2 SUSD2 TANC1 HYDIN	5.17e-05	192	152	6	0644fad5df18f0021f6f49cca996d8cf47f972ff
ToppCell	Control-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	VWA3A DNAH3 LDLRAD1 ADGB KIAA0825 HYDIN	5.32e-05	193	152	6	0e37d454f3735edd936ee9a5f5f516ac3aad400e
ToppCell	IPF-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	VWA3A DNAH3 LDLRAD1 ADGB KIAA0825 HYDIN	5.32e-05	193	152	6	ad58f5080e0ba65c845056ea6b79037b636e9c64
ToppCell	severe_influenza-RBC\|severe_influenza / disease group, cell group and cell class (v2)	TMPRSS9 CTNNAL1 HMBS FAXDC2 ADD2 PHLPP2	5.32e-05	193	152	6	ffb0b3c2cce13b6891157f0fede2600f3938670e
ToppCell	NS-critical-d_07-13-Epithelial-Ciliated\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.47e-05	194	152	6	1ae8a10e508e672e6677f0e3c986ac30d05adeb3
ToppCell	ASK452-Epithelial-Ciliated\|ASK452 / Donor, Lineage and Cell class of Lung cells from Dropseq	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.47e-05	194	152	6	5aeb44657ab6f61b1abf98af28d3397d8e44c1aa
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	VWA3A DNAH3 LDLRAD1 ADGB WDR90 HYDIN	5.47e-05	194	152	6	4a2c127c90d1fefe604fcb9e796577d21b489dd6
ToppCell	(2)_Mono_macro\|World / Oesophagus cell shreds on cell class (v1) and cell subclass (v1)	SIGLEC14 CSF2RA FCGR1A CSF3R FCGR1BP C5AR1	5.47e-05	194	152	6	7c05525614ee8cdfcbf22cce9146a8e73af7d14e
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.63e-05	195	152	6	68f4cc84b5ae7f4159b780c78e4b66c94211779a
ToppCell	AT1_cells\|World / lung cells shred on cell class, cell subclass, sample id	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.63e-05	195	152	6	792d6a49b0a875a00569071183d195287a9925c5
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.63e-05	195	152	6	2a1863f4b9fe73c30b0b1acf9b12fc98ef65040f
ToppCell	moderate-Epithelial-Ciliated\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.63e-05	195	152	6	3486eae5fdb062a75a907b896c9d7b396d2aa195
ToppCell	moderate-Epithelial-Ciliated\|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.63e-05	195	152	6	e80f5cdf0b18066b3e6c2f5452e58f101c67932c
ToppCell	cellseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.79e-05	196	152	6	6731fef8c148b6681d6ed38afdf23c8213e0bbbe
ToppCell	Epithelial_cells-AT1_cells\|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.79e-05	196	152	6	6c99d29162848161c1f166a032320f87a5d5a631
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1-AT1_L.0.5.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.79e-05	196	152	6	eb68f7954e7c2f86d05e740e95b6e74805a6053f
ToppCell	cellseq-Epithelial-Epithelial_Alveolar-AT1\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.79e-05	196	152	6	6856317cd0cdcb88fe54b4ae905d91e13495b1c4
ToppCell	NS-control-d_0-4-Epithelial-Ciliated\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.79e-05	196	152	6	d46ab80554dd3c1cc81e1938ea2acfd5e85c6d2a
ToppCell	distal-1-Epithelial-Alveolar_Epithelial_Type_1\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CLIC3 MAL2 SUSD2 EFR3B MYRF ANKRD33B	5.96e-05	197	152	6	d44b7dc7c6416ed9466889374c3ae39f43ac8bb6
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.96e-05	197	152	6	c9c968e223e7814cd8d22975d849a31b7e0af7aa
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.96e-05	197	152	6	91637bdeab85024b5a02d1066f76cb803a2d6420
ToppCell	severe-Myeloid-Neutrophils_2\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	SAMD9 IFIT1 FCGR1A CSF3R FCGR1BP C5AR1	5.96e-05	197	152	6	c8a90d82170cf20e14aebecddcf7cc0ca56cda87
ToppCell	AT1_cells-Donor_06\|World / lung cells shred on cell class, cell subclass, sample id	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.96e-05	197	152	6	80d81be244c94c435accb643449b4ce6a3462c7f
ToppCell	control-Epithelial-Ciliated\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.96e-05	197	152	6	e453d085182364ca347cbcc9dc995c62c3353016
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1-AT1_L.0.5.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.96e-05	197	152	6	734b8db5bb4917c9ce92ed342fe6c22b64b0d3c5
ToppCell	control-Myeloid-Neutrophils_2\|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	SAMD9 IFIT1 FCGR1A CSF3R FCGR1BP C5AR1	5.96e-05	197	152	6	8819db1550bf14566c6d33d97f7f83419e867ace
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_I_pneumocyte-AT1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	5.96e-05	197	152	6	e344455e62b3fe94bb242dc0db58d19a1d3878c7
ToppCell	control-Epithelial-Ciliated\|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	5.96e-05	197	152	6	d4e963c1f82996371bf3d63578ee9fce8e00c5a8
ToppCell	COVID-19_Severe-Classical_Monocyte\|World / disease group, cell group and cell class	SIGLEC14 IFIT1 FCGR1A CSF3R FCGR1BP C5AR1	5.96e-05	197	152	6	344801997b89bd81d8d5c3c872934de523233a8d
ToppCell	Biopsy_IPF-Epithelial-AT1\|Biopsy_IPF / Sample group, Lineage and Cell type	ROR1 CLIC3 SCUBE1 SUSD2 EFR3B MYRF	6.13e-05	198	152	6	75bdecbe111fededf6082b11de18b84ca308ef6d
ToppCell	severe-Myeloid-Neutrophils_2\|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	SAMD9 IFIT1 FCGR1A CSF3R FCGR1BP C5AR1	6.13e-05	198	152	6	636878836678a0715550fa09f2e3dac11c4d73fe
ToppCell	Caecum-(6)_Macrophage-(61)_LYVE1_Macrophage\|Caecum / shred on region, Cell_type, and subtype	SIGLEC14 SSPOP FCGR1A CSF3R FCGR1BP C5AR1	6.13e-05	198	152	6	e684c3934c163aef4d284b69435832d2c9614f2a
ToppCell	Caecum-Macrophage-LYVE1_Macrophage\|Caecum / Region, Cell class and subclass	SIGLEC14 SSPOP FCGR1A CSF3R FCGR1BP C5AR1	6.13e-05	198	152	6	a92c0cacb775aca6bbb302bd9e22c081a112a44d
ToppCell	3'-GW_trimst-2-SmallIntestine-Epithelial-mature_enterocytic\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	XDH AGXT2 OTC ETHE1 SLC39A5 SOAT2	6.30e-05	199	152	6	1e6ac65ce7133de4872dcd7e98e2a9e57d3d61b7
ToppCell	Parenchymal-10x3prime_v2-Immune_Myeloid-Monocytic-Monocyte_CD16\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	SIGLEC14 FCGR1A CSF3R FCGR1BP C5AR1 MYO18B	6.30e-05	199	152	6	36662a76211162b1bf2d58dc819cae339f715c5f
ToppCell	LPS_anti-TNF-Hematopoietic_Erythro-Megakary\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	TMPRSS9 HMBS FAXDC2 IFIT1 CYP4F22 PHLPP2	6.30e-05	199	152	6	6c174dbcc25b980f10a3d1dfe39e613acac73bb6
ToppCell	3'-GW_trimst-2-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	XDH AGXT2 OTC ETHE1 SLC39A5 SOAT2	6.30e-05	199	152	6	38432e3ccbc546dc4c1dc2fb1d8d44f8a6de9424
ToppCell	LPS_anti-TNF-Hematopoietic_Erythro-Megakary-Erythro-Mega\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	TMPRSS9 HMBS FAXDC2 IFIT1 CYP4F22 PHLPP2	6.30e-05	199	152	6	284ee9632413f6404fc0b0c7c393ad813db834f2
ToppCell	Transverse-(4)_Monocyte\|Transverse / shred on region, Cell_type, and subtype	SIGLEC14 CSF2RA FCGR1A CSF3R FCGR1BP C5AR1	6.48e-05	200	152	6	85714e8da539366b5bce071dfea8f8055de527bc
ToppCell	Transverse-Monocyte-Monocyte\|Transverse / Region, Cell class and subclass	SIGLEC14 CSF2RA FCGR1A CSF3R FCGR1BP C5AR1	6.48e-05	200	152	6	96ecfab57e998134e164b4a62881ef6f2612bd8d
ToppCell	Transverse-Monocyte\|Transverse / Region, Cell class and subclass	SIGLEC14 CSF2RA FCGR1A CSF3R FCGR1BP C5AR1	6.48e-05	200	152	6	d70aeb57b98496474b97906505576640fdbdf34c
ToppCell	Bronchus_Control_(B.)-Epithelial-TX-Ciliated\|Bronchus_Control_(B.) / Sample group, Lineage and Cell type	VWA3A DNAH3 LDLRAD1 ADGB WDR90 HYDIN	6.48e-05	200	152	6	6a2ccc71a0cbe04a542c379b28b5006de53981c3
ToppCell	mLN-Macrophage\|mLN / Region, Cell class and subclass	CYFIP1 CSF2RA FCGR1A CSF3R FCGR1BP C5AR1	6.48e-05	200	152	6	68d709afd226241e002dae6d6820bccd1cfd87a1
ToppCell	distal-2-Epithelial-Alveolar_Epithelial_Type_1\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	ROR1 CLIC3 MAL2 SUSD2 EFR3B MYRF	6.48e-05	200	152	6	313ec1e53bd738a9cb48dc5b946261156f99f44b
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_alveolar-AT1\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CLIC3 MAL2 SCUBE1 SUSD2 EFR3B MYRF	6.48e-05	200	152	6	3d51aebf626dd4656ab4aac8a20d761b8062c42d
ToppCell	Biopsy_IPF-Epithelial-Ciliated\|Biopsy_IPF / Sample group, Lineage and Cell type	VWA3A DNAH3 LDLRAD1 ADGB CC2D2A HYDIN	6.48e-05	200	152	6	bb8c99156e547a8eb6599b6b6bc3c66bf77af7f8
Disease	MEHMO syndrome (implicated_via_orthology)	EIF2S3B EIF2S3	2.47e-05	2	147	2	DOID:0060801 (implicated_via_orthology)
Disease	spastic quadriplegic cerebral palsy 3 (implicated_via_orthology)	ADD1 ADD2	7.37e-05	3	147	2	DOID:0081361 (implicated_via_orthology)
Disease	4-hydroxyphenylacetylglutamine measurement	DNAH3 ACSM1	7.37e-05	3	147	2	EFO_0800688
Disease	retinal degeneration (biomarker_via_orthology)	KCNH8 FCGR1A FCGR1BP	3.62e-04	28	147	3	DOID:8466 (biomarker_via_orthology)
Disease	hypopituitarism (implicated_via_orthology)	EIF2S3B EIF2S3	3.65e-04	6	147	2	DOID:9406 (implicated_via_orthology)
Disease	neutropenia (implicated_via_orthology)	CSF3R C5AR1	5.09e-04	7	147	2	DOID:1227 (implicated_via_orthology)
Disease	cholesteryl ester 16:2 measurement	AREL1 LTBP3	5.09e-04	7	147	2	EFO_0021435
Disease	leukodystrophy (implicated_via_orthology)	EIF2S3B EIF2S3	8.67e-04	9	147	2	DOID:10579 (implicated_via_orthology)
Disease	gallbladder neoplasm	CNTN4 KIAA0825	8.67e-04	9	147	2	EFO_0004606
Disease	cerebral palsy (implicated_via_orthology)	ADD1 ADD2	1.08e-03	10	147	2	DOID:1969 (implicated_via_orthology)
Disease	Mitral valve prolapse, response to surgery	AREL1 LTBP3	1.57e-03	12	147	2	EFO_0009951, HP_0001634
Disease	11beta-hydroxyandrosterone glucuronide measurement	XDH SLC22A8	1.57e-03	12	147	2	EFO_0800573
Disease	Influenza	SAMD9 IFIT1 SLC22A8	2.24e-03	52	147	3	C0021400
Disease	phosphatidylcholine 38:6 measurement	TMTC4 MYRF	2.83e-03	16	147	2	EFO_0010388
Disease	central nervous system disease (implicated_via_orthology)	ACO2 SEC31B	2.83e-03	16	147	2	DOID:331 (implicated_via_orthology)
Disease	renal fibrosis (implicated_via_orthology)	GPR21 XDH	3.19e-03	17	147	2	DOID:0050855 (implicated_via_orthology)
Disease	phosphatidylcholine 40:6 measurement	TMTC4 MYRF	3.19e-03	17	147	2	EFO_0010389
Disease	hypertension (is_implicated_in)	XDH ADD1 ADD2 AGXT2	3.20e-03	121	147	4	DOID:10763 (is_implicated_in)
Disease	hydrocephalus (implicated_via_orthology)	ADD1 HYDIN	3.99e-03	19	147	2	DOID:10908 (implicated_via_orthology)
Disease	pulse pressure measurement	WDR7 FRYL PNKD SSPOP MAL2 FBXO38 FCSK AREL1 CYFIP1 INTS11 YDJC LTBP3 DDHD2 ARMH3 HYDIN	4.11e-03	1392	147	15	EFO_0005763
Disease	serum homoarginine measurement	AGXT2 ANKRD33B	4.42e-03	20	147	2	EFO_0005421
Disease	haptoglobin measurement	HYDIN PHLPP2	4.86e-03	21	147	2	EFO_0004640

Protein segments in the cluster

Peptide	Gene	Start	Entry
IHLVGPSDCTLHGFV	ACOT7	231	O00154
PSTIHCDHLIEAQVG	ACO2	121	Q99798
IVTVSVGHCHPKVNA	AGXT2	111	Q9BYV1
HAGLCSTHEQHILVP	FAM228A	191	Q86W67
HISGAHINPAVTVAC	AQP2	61	P41181
GTPVEETLHACQRLH	AKR7A2	146	O43488
EYGLSHICSHPVLVT	ADGB	446	Q8N7X0
HIVDTVCAHFRQAPI	CLIC3	181	O95833
PLTACHVAQELHFIE	ATP13A1	751	Q9HD20
SGLAAKFVIHCHIPQ	MACROH2A2	266	Q9P0M6
VFFVIHLHAGPVINT	CREBBP	1631	Q92793
VGESIVLPCQVTHDH	CNTN4	511	Q8IWV2
VLPCQVTHDHSLDIV	CNTN4	516	Q8IWV2
LTEVITAAEFHPHQC	PPP2R2D	231	Q66LE6
SPEHVCQHLEQVLLG	C1orf74	96	Q96LT6
LFQHCIQALGEEHPI	ARMH3	81	Q5T2E6
CSIILSHHQGPSIIN	ANKRD55	211	Q3KP44
LVFDDHGQLSHVPCV	DNHD1	561	Q96M86
ALHLCGHVDTIQFLV	ANKRD46	81	Q86W74
CLALPILFTSIVQHH	C5AR1	86	P21730
IGCNPTILHVHELYI	BCKDK	116	O14874
NFCSEEVVSLHVPVH	BBS12	121	Q6ZW61
EVVSLHVPVHNIFDC	BBS12	126	Q6ZW61
LEIFCSEIGVNHTHL	FAM200A	281	Q8TCP9
IRAHTPACHLLGEVQ	ADAMTS7	121	Q9UKP4
HGFVDTVVALAECPH	ANKRD33B	131	A6NCL7
QCRGQSVILPHLTHF	RCBTB2	336	O95199
VEHVRCFQPPIHQSL	CYFIP1	1236	Q7L576
EETVTLHCEVLHLPG	FCGR1BP	36	Q92637
IIRNCPSFDIHTIHV	FASTK	146	Q14296
LRGTQSPVHALHFCE	GNB1L	16	Q9BYB4
CSQIIDHSHVPEFEV	GPR39	11	O43194
VSVLNFHLLHQLPGC	GPR88	226	Q9GZN0
HRGAVHALVTTECPQ	KIAA0825	316	Q8IV33
HCVQHLPDGSVTVES	INTS11	541	Q5TA45
SGKCVLHPTTLLQEH	KIAA1109	3801	Q2LD37
GHLCVLEPSVSAQHI	IKBKE	356	Q14164
PACKHHTLVGFLATE	PCNX1	2201	Q96RV3
ATDPQIVTTDLHHGC	PCSK4	351	Q6UW60
TILHVICTDATLHGP	OR51G1	46	Q8NGK1
GHPCFLTTQDIHLGV	OTC	106	P00480
LTTVPAFCQHIHEVI	EFR3B	606	Q9Y2G0
CLLPHLIQHFDSPTQ	FRYL	2106	O94915
ISVDIHCGEPLQIDH	DDHD2	201	O94830
HCGEPLQIDHLVFVV	DDHD2	206	O94830
VPTGTNVLFLHHIEC	PINLYP	186	A6NC86
VHSGLIGPLLVCHTN	F8	1866	P00451
VPQSLPHFLVAHCGD	LDLRAD1	116	Q5T700
HPEVSIEHLGQVVQC	MUC5AC	3276	P98088
LIGFLVHHASPGCVN	MROH6	621	A6NGR9
TPLHASVINGHTLCL	ANKRD44	636	Q8N8A2
CKVIPVHQHLLGTTS	PSMB11	81	A5LHX3
HICAVLGTHFQLEAV	PAQR6	261	Q6TCH4
FLGDGCHVTHVLPNV	OOSP1	56	A8MZH6
TIAEHAPVGHCFLQV	DCHS2	671	Q6V1P9
TICFAPSNIILIIHH	F2RL2	311	O00254
HICIIHEFSNPPNVR	FBXO38	1026	Q6PIJ6
ICAGIVHVHSELQLS	FCSK	801	Q8N0W3
LQHFHSESKPICAVG	GATD1	111	Q8NB37
PGFHTLHTILGVQCL	GSAP	696	A4D1B5
IITTISHCGYHLPFL	FAXDC2	256	Q96IV6
SPCVAASQHGVTHLI	CRNKL1	66	Q9BZJ0
GQLFSPLCLSHEVHT	HEATR3	406	Q7Z4Q2
IHHTVFIGETLDLPC	IGSF10	581	Q6WRI0
PALHLVNTEVDFGHC	HYDIN	696	Q4G0P3
EPIEHVTACLQALHT	HEATR5B	1606	Q9P2D3
LDIDISGLIFTHHPC	CC2D2A	406	Q9P2K1
HISGTEPLEITCIHA	CTNNAL1	456	Q9UBT7
HIAVVFIPCGHLVTC	BIRC8	196	Q96P09
VIQGVLLCPHTHLQD	DNAH3	2281	Q8TD57
VIVTCPGCQNHHIIA	DNLZ	96	Q5SXM8
AVIPGCHLHPFNVTV	GPHA2	26	Q96T91
IVVLHACAHNPTGID	GOT1	186	P17174
VCHFSTLVLTCGQPH	AREL1	171	O15033
LVVQHGHCSYTFLLP	ANGPT4	36	Q9Y264
CGHISVSAPIVHLGD	CSF3R	26	Q99062
LHDLHCNTTITGQPL	MAL2	126	Q969L2
FRLVSPEHQCQHPLT	LTBP3	406	Q9NS15
HSVHEKIFTLPGDCL	ETHE1	176	O95571
TPGGLHVELHSECVT	FBXO40	451	Q9UH90
IHIVFSRSPINCLEH	TMEM259	86	Q4ZIN3
TPTSVLLHHQIGLCY	IFIT1	281	P09914
EETVTLHCEVLHLPG	FCGR1A	36	P12314
LTVVQHGIPCCEVHI	HBP1	316	O60381
LGPVCEAVHSHFLSL	ERMARD	71	Q5T6L9
LVRHVSFVDCPGHDI	EIF2S3B	126	Q2VIR3
HLEGGCSVPVAVHTA	HMBS	256	P08397
HHPLPVEESLTCQIF	GPR21	91	Q99679
LPAVDETTCGHTHFQ	CEP295	2031	Q9C0D2
LLQIFTAATPVHHCR	SLC22A8	36	Q8TCC7
ARQPLLDHCHVTFVT	SCUBE1	511	Q8IWY4
PQSSVLLCHIGVVQH	CDC27	666	P30260
HVANICFAVGLVIPT	BVES	46	Q8NE79
CFAVGLVIPTTLHLH	BVES	51	Q8NE79
ICLVSIYGTHHNPTV	CYP4F22	426	Q6NT55
CPVHPTELVFALDHS	COL6A6	1751	A6NMZ7
ICLHEGVTFEVHVNT	CSF2RA	86	P15509
CFSTHLVSQHGEPGI	NUP210L	1496	Q5VU65
IIPHTYCEHIGVAQL	OR52H1	181	Q8NGJ2
VTLFIGHTICYHPQA	MROH5	1256	Q6ZUA9
VCHILLLVHPTCSFD	SMG8	206	Q8ND04
PVLTHATTVAVAHGC	FOXN4	326	Q96NZ1
SPFHEHVLGALCSLV	HSPBP1	286	Q9NZL4
GSISHVLVQLPHVFQ	UTP25	566	Q68CQ4
HVDSSGQVHCVSPLL	SUSD2	106	Q9UGT4
HPLCHQDVVSVGRLQ	PNKD	206	Q8N490
VHHSDVPLQVELLGC	SSPOP	2211	A2VEC9
ENILCICVHPHIFQG	SAMD9	571	Q5K651
GVPHILEHTVLCGSQ	PITRM1	101	Q5JRX3
AVCIIVAVHFGPRLH	SMIM33	56	A0A1B0GW64
TLCETVHVHGLPVTR	SIN3B	1136	O75182
APILCVQSHLGHEEV	TANC1	936	Q9C0D5
FLHPCTQQILEVHLV	SPATA31E1	826	Q6ZUB1
TIGINQPHLAFLHIC	MT-ND5	316	P03915
RIIELCHQFPHGITD	POLR3F	21	Q9H1D9
LSPHVVAGLHEVARC	SEC31B	1121	Q9NQW1
DITPVLDHTFCVEHN	SMURF1	546	Q9HCE7
TTLAVFCHELPHELG	SLC39A5	416	Q6ZMH5
AHAVVLCALPVHVAV	SOAT2	206	O75908
PRHVISSVLGHCKFN	ACTRT1	31	Q8TDG2
DVRCIIHLHTPATAA	ADD2	221	P35612
CVVHIHTPAGAAVSA	ADD1	236	P35611
GCTVFIHHLPQFDTK	ACSM1	286	Q08AH1
HHPNIVCLLGAVTQE	ROR1	531	Q01973
LAALLFAVHPVHTEC	TMTC4	151	Q5T4D3
FAVHPVHTECVAGVV	TMTC4	156	Q5T4D3
SCLIVHQRIHSGDLP	ZNF35	431	P13682
GLCQHLIFPHSTTVL	WDR90	1196	Q96KV7
GAHKDCQVAPLTHVF	TRIM55	151	Q9BYV6
THCVRPFCSLIQIHG	NAA35	426	Q5VZE5
LLTDQCIPVLVGHLH	PHLPP2	631	Q6ZVD8
GILISPQHVLTAAHC	PRSS35	156	Q8N3Z0
IPLHNACSFGHAEVV	TNKS	251	O95271
SFHGIVCTAPQLNIH	TPP2	751	P29144
RHIQPVCLPAATHIF	TMPRSS9	306	Q7Z410
HVHVLPGVCQVFAEA	YDJC	136	A8MPS7
PICSLHHVAVTTVEG	XDH	76	P47989
IQHQSIHTGEKPFEC	ZNF780A	181	O75290
GLPVTCEVAPHHLFL	CAD	1631	P27708
LHFIHCLVPNPVVES	MYO18B	1196	Q8IUG5
LGPAVIIFHETVHTQ	ZFYVE1	311	Q9HBF4
SFHLVVHLIASCIDP	ZDHHC11	81	Q9H8X9
VPLELHIQGFNISHT	SNRNP200	1521	O75643
TLHQSIHTGEKPFEC	ZFP82	466	Q8N141
EILHCLGPHNQESTV	ERVK-18	66	P63123
HTVIAHSNCIEVFPE	PHLPP1	1086	O60346
DIHTSRVVAHVLPCG	RCHY1	151	Q96PM5
VCFHPTEAHVLLSGS	WDR24	126	Q96S15
SFHLVVHLIASCIDP	ZDHHC11B	81	P0C7U3
HIFCVHGGEITQLLV	WDR7	506	Q9Y4E6
PLHSFQAHQSGVICI	WDR87	236	Q6ZQQ6
SHVPLRLFVDHCVAT	ZP3	206	P21754
PLHVSCLLLVTDEHG	ZMYND15	201	Q9H091
QHIRTHTGEKPFVCV	ZNF426	381	Q9BUY5
EFTCRVQHPLGSQHL	SIGLEC14	316	Q08ET2
CSIFPSVEIHGVVRH	VWA3A	901	A6NCI4
THGPFETCLLHVKAA	ZAN	1361	Q9Y493
QHEPHCPVSITRAIA	nan	66	Q8N9L7
QGVRLDNCHSTPLHV	AGL	521	P35573
LVRHVSFVDCPGHDI	EIF2S3	126	P41091
VQEGHLQFLRCISPH	KCNH8	1001	Q96L42
HLLRTITPETLCHVG	MYRF	156	Q9Y2G1